Five-year_survival_for_cisplatin-based_chemotherapy_versus_single-agent_melphalan_in_patients_with_advanced_ovarian_cancer_and_optimal_debulking_surgery._The_purpose_of_this_study_was_to_evaluate_5-year_survival_and_5-year_progression-free_survival_in_previously_untreated_patients_with_advanced_ovarian_cancer_treated_with_single-agent_melphalan_in_which_very_few_patients_underwent_optimal_debulking_surgery_(less_than_2_cm_residual)_as_compared_with_the_patients_treated_with_Cisplatin-based_chemotherapy_in_which_most_patients_underwent_optimal_debulking_surgery._Significant_increases_in_5-year_survival_and_5-year_progression-free_survival_were_noted_as_we_changed_from_the_melphalan_trial,_in_which_only_14%_underwent_optimal_debulking_surgery,_to_PAC-H,_in_which_57%_and_the_PAC_trial_in_which_90%,_respectively,_underwent_optimal_debulking_surgery._However,_for_those_patients_whose_tumors_were_optimally_debulked_in_the_three_trials,_there_were_no_statistically_significant_differences_in_median_survival,_median_progression-free_survival,_5-year_survival,_or_5-year_progression-free_survival_in_those_patients_treated_with_melphalan,_PAC-H,_or_PAC._Without_optimal_debulking_surgery,_Cisplatin-based_multiagent_chemotherapy_offered_a_small_survival_advantage._These_results_are_similar_to_that_reported_by_Gruppo_Interregionale_Cooperativo_Oncologico_Ginecologia,_in_which_survival_curves_were_identical_for_all_the_subgroups_of_chemotherapy_regimens_for_those_patients_with_residual_disease_less_than_2_cm_at_the_onset_of_chemotherapy_whether_they_received_(1)_cyclophosphamide;_(2)_cyclophosphamide_and_Adriamycin;_(3)_cyclophosphamide,_Adriamycin,_and_Cisplatin;_(4)_cyclophosphamide,_Adriamycin,_and_hexamethylmelamine;_(5)_Cisplatin_and_cyclophosphamide;_(6)_low-dose_Cisplatin;_(7)_high-dose_Cisplatin;_or_(8)_carboplatin.